Alzheon sets IPO pricing terms

Framingham, Massachusetts-based Alzheon Inc, a biopharmaceutical company focused on brain health, memory and aging, has priced 5 million shares of its IPO at between $13 and $15 per share. The stock will trade on the NASDAQ under the ticker symbol “ALZH.” Citigroup Global Markets Inc. and Piper Jaffray & Co. are the lead underwriters. Alzheon’s backers include Ally Bridge Group.

PRESS RELEASE

FRAMINGHAM, Mass.–(BUSINESS WIRE)–Alzheon, Inc. (“Alzheon”) announced today that it has launched the roadshow for the initial public offering of its common stock. Alzheon is offering 5,000,000 shares of its common stock at an initial public offering price between $13.00 and $15.00 per share. Alzheon expects to grant the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions, to cover over-allotments. The shares are expected to trade on The Nasdaq Global Market under the ticker symbol “ALZH.”

Citigroup Global Markets Inc. and Piper Jaffray & Co. are acting as joint book-running managers for the offering. Canaccord Genuity LLC and JMP Securities LLC are acting as co-managers for the offering.

The offering is being made only by means of a prospectus. A copy of the preliminary prospectus related to the offering may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146; or Piper Jaffray & Co., 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, Attention: Prospectus Department, by telephone at (800) 747-3924 or by email at prospectus@pjc.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.